| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 285.4% | Cantor Fitzgerald | → $19 | Reiterates | Overweight → Overweight |
| 07/11/2023 | 285.4% | Cantor Fitzgerald | → $19 | Initiates Coverage On | → Overweight |
| 05/25/2023 | 62.27% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 03/24/2023 | 62.27% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 09/29/2020 | 62.27% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 01/10/2020 | 62.27% | Craig-Hallum | → $8 | Initiates Coverage On | → Buy |
| 12/23/2019 | — | Laidlaw & Co. | Initiates Coverage On | → Buy | |
| 12/23/2019 | 102.84% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
What is the target price for Soleno Therapeutics (SLNO)?
The latest price target for Soleno Therapeutics (NASDAQ: SLNO) was reported by Cantor Fitzgerald on August 31, 2023. The analyst firm set a price target for $19.00 expecting SLNO to rise to within 12 months (a possible 285.40% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Soleno Therapeutics (SLNO)?
The latest analyst rating for Soleno Therapeutics (NASDAQ: SLNO) was provided by Cantor Fitzgerald, and Soleno Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Soleno Therapeutics (SLNO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Soleno Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Soleno Therapeutics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
Is the Analyst Rating Soleno Therapeutics (SLNO) correct?
While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a reiterated with a price target of $0.00 to $19.00. The current price Soleno Therapeutics (SLNO) is trading at is $4.93, which is within the analyst's predicted range.